Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(CNA-0893) Acetyl L Carnitine in Depression


 Return to List of Clinical Studies
 Return to List of Protocols for Neurologic and Psychiatric Disorders
Acetyl-L-carnitine: toward next-generation antidepressant therapies and metabolomics biomarkers for depressive disorders

Principal Investigator:
Carla Nasca PhD

Investigators:
Bruce S. McEwen PhD
Benedetta Bigio MS

Contact Information:
Ashly Cochran
Enrollment only at WCMC; contact information below:
525 E. 68th St., Rm. F-1319
New York, NY 10065
Telephone: (212) 746-3754
FAX: (212) 746-59
Email: asc2005@med.cornell.edu
Enrollment Status:
Open to Enrollment

Brief Summary of Protocol:
Depression is a severe debilitating and common disorder that displays a variety of types with symptoms, like sadness, irritability, abnormalities in appetite and sleep, thinking disturbances with excessive worrying, guilt, and possibly suicidal ideation. All those symptoms interfere with the personal, social and working everyday life. Unfortunately, current antidepressant treatments require several weeks/months before showing any efficacy. Also, approximately 40% of depressed patients do not respond to current antidepressant medications. A major goal in developing successful treatments is the improvement of the diagnosis, which is currently made only on the identifications of symptoms scored by the clinician subjectively. The identification of a valid and objective biological marker (biomarker) would improve the accuracy of the diagnosis and help to develop better treatments. In our preclinical studies, we found that a nutritional factor, called acetyl-L-carnitine (LAC) was lower in animals with features of depression. Thus, the goal of this study is to determine if LAC or molecules related to LAC may show alterations in people with different types of depression in comparison with healthy volunteers. If so, one or more of these molecules could be used as marker for the diagnosis of depression. Findings from this study could also help us in developing better treatments.



Detailed Description of Protocol:




What specifically makes a person eligible for the study?
You may be eligible to enter this study:



Gender:
Both

Age(s):
18-100

Children permitted to participate:
No

Potential Benefits.....




Compensation: